東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Co-Delivery of Immunomodulators and ...

Northrup, Laura.

FindBook

Google Book

Amazon

博客來

Co-Delivery of Immunomodulators and Autoantigen as Antigen-Specific Immunotherapy for the Treatment of a Murine Model of Multiple Sclerosis.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Co-Delivery of Immunomodulators and Autoantigen as Antigen-Specific Immunotherapy for the Treatment of a Murine Model of Multiple Sclerosis./
作者:	Northrup, Laura.
出版者:	Ann Arbor : ProQuest Dissertations & Theses, : 2016,
面頁冊數:	184 p.
附註:	Source: Dissertation Abstracts International, Volume: 78-06(E), Section: B.
Contained By:	Dissertation Abstracts International78-06B(E).
標題:	Pharmaceutical sciences. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=10242701
ISBN:	9781369538762

Co-Delivery of Immunomodulators and Autoantigen as Antigen-Specific Immunotherapy for the Treatment of a Murine Model of Multiple Sclerosis.
Northrup, Laura.

Co-Delivery of Immunomodulators and Autoantigen as Antigen-Specific Immunotherapy for the Treatment of a Murine Model of Multiple Sclerosis. - Ann Arbor : ProQuest Dissertations & Theses, 2016 - 184 p.

Source: Dissertation Abstracts International, Volume: 78-06(E), Section: B.

Thesis (Ph.D.)--University of Kansas, 2016.

Multiple Sclerosis (MS) is an autoimmune disease characterized by the breakdown of immune tolerance towards autoantigen in the myelin sheath surrounding the neurons. Current therapies for MS and other autoimmune diseases focus on treating the symptoms and not the cause of the disease. A major setback in improving current therapeutics for autoimmunity is the lack of antigen specificity. Successful antigen-specific immunotherapy (ASIT) would allow for improved treatment of autoimmune diseases. This thesis investigates the creation of ASIT for autoimmunity through the co-delivery of an immunomodulator and autoantigen. First, immunomodulatory peptides targeting the B7 costimulatory pathway and cell adhesion were tested for their ability to suppress a murine model of MS, experimental autoimmune encephalomyelitis (EAE), utilizing a co-delivery vehicle developed in our lab, soluble antigen arrays. Peptides targeting different surface markers were all found to suppress EAE when co-delivered with autoantigen, demonstrating the ability of different immunomodulators to create effective ASIT. Expanding upon the idea of combinational ASIT, eleven different small molecules immunomodulators were screened for properties indicative of autoimmune suppression in an antigen-specific splenocyte system. This screen revealed that several compounds, most notably dexamethasone, had the ability to skew the antigen-specific immune response towards autoimmune suppression. The ability of dexamethasone to act as an effective immunomodulator in ASIT for autoimmunity was confirmed in vivo in the treatment of EAE. Co-delivery of dexamethasone and autoantigen in an oil-in-water emulsion, incomplete Freund's adjuvant, was found to suppress EAE and shift the immune response. Overall, the results presented dissertation provide evidence for the successful creation of ASIT for autoimmunity by combining immunomodulator and autoantigen.

ISBN: 9781369538762Subjects--Topical Terms:

3173021
Pharmaceutical sciences.

Co-Delivery of Immunomodulators and Autoantigen as Antigen-Specific Immunotherapy for the Treatment of a Murine Model of Multiple Sclerosis.
LDR:02920nmm a2200301 4500 001 2126684
005 20171128092618.5
008 180830s2016 ||||||||||||||||| ||eng d
020 $a 9781369538762
035 $a (MiAaPQ)AAI10242701
035 $a AAI10242701
040 $a MiAaPQ $c MiAaPQ
100 1 $a Northrup, Laura. $3 3288794
245 1 0 $a Co-Delivery of Immunomodulators and Autoantigen as Antigen-Specific Immunotherapy for the Treatment of a Murine Model of Multiple Sclerosis.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2016
300 $a 184 p.
500 $a Source: Dissertation Abstracts International, Volume: 78-06(E), Section: B.
500 $a Adviser: Cory Berkland.
502 $a Thesis (Ph.D.)--University of Kansas, 2016.
520 $a Multiple Sclerosis (MS) is an autoimmune disease characterized by the breakdown of immune tolerance towards autoantigen in the myelin sheath surrounding the neurons. Current therapies for MS and other autoimmune diseases focus on treating the symptoms and not the cause of the disease. A major setback in improving current therapeutics for autoimmunity is the lack of antigen specificity. Successful antigen-specific immunotherapy (ASIT) would allow for improved treatment of autoimmune diseases. This thesis investigates the creation of ASIT for autoimmunity through the co-delivery of an immunomodulator and autoantigen. First, immunomodulatory peptides targeting the B7 costimulatory pathway and cell adhesion were tested for their ability to suppress a murine model of MS, experimental autoimmune encephalomyelitis (EAE), utilizing a co-delivery vehicle developed in our lab, soluble antigen arrays. Peptides targeting different surface markers were all found to suppress EAE when co-delivered with autoantigen, demonstrating the ability of different immunomodulators to create effective ASIT. Expanding upon the idea of combinational ASIT, eleven different small molecules immunomodulators were screened for properties indicative of autoimmune suppression in an antigen-specific splenocyte system. This screen revealed that several compounds, most notably dexamethasone, had the ability to skew the antigen-specific immune response towards autoimmune suppression. The ability of dexamethasone to act as an effective immunomodulator in ASIT for autoimmunity was confirmed in vivo in the treatment of EAE. Co-delivery of dexamethasone and autoantigen in an oil-in-water emulsion, incomplete Freund's adjuvant, was found to suppress EAE and shift the immune response. Overall, the results presented dissertation provide evidence for the successful creation of ASIT for autoimmunity by combining immunomodulator and autoantigen.
590 $a School code: 0099.
650 4 $a Pharmaceutical sciences. $3 3173021
650 4 $a Immunology. $3 611031
650 4 $a Biomedical engineering. $3 535387
690 $a 0572
690 $a 0982
690 $a 0541
710 2 $a University of Kansas. $b Pharmaceutical Chemistry. $3 1265020
773 0 $t Dissertation Abstracts International $g 78-06B(E).
790 $a 0099
791 $a Ph.D.
792 $a 2016
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=10242701